

1 **Age-adjusted Charlson comorbidity index score is the best predictor for severe clinical**  
2 **outcome in the hospitalized patients with COVID-19 infection: a result from nationwide**  
3 **database of 5,621 Korean patients**

4

5 Do Hyoung Kim<sup>†1,2</sup>, Hayne Cho Park<sup>†1,2</sup>, Ajin Cho<sup>1,2</sup>, Juhee Kim<sup>1</sup>, Kyu-sang Yun<sup>1</sup>, Jinseog  
6 Kim<sup>3</sup>, Young-Ki Lee<sup>1,2</sup>

7

8 <sup>1</sup>Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University  
9 College of Medicine, Seoul, Korea.

10 <sup>2</sup>Hallym University Kidney Research Institute, Seoul, Korea.

11 <sup>3</sup>Department of Bigdata and Applied Statistics, Dongguk University, Gyeongju, Korea.

12

13 <sup>†</sup>Do Hyoung Kim and Hayne Cho Park contributed equally to this work.

14

15 **CORRESPONDENCE:**

16 Young-Ki Lee

17 Address: 1, Singil-ro, Yeongdeungpo-gu, Seoul, 07441, Korea

18 Phone: (Int. +82-2) 829-5214

19 E-mail: km2071@naver.com

20 **ABSTRACT**

21 Aged population with comorbidities demonstrated high mortality rate and severe clinical  
22 outcome in the patients with coronavirus disease 2019 (COVID-19). However, whether age-  
23 adjusted Charlson comorbidity index score (CCIS) predict fatal outcomes remains uncertain.  
24 This retrospective, nationwide cohort study was performed to evaluate patient mortality and  
25 clinical outcome according to CCIS among the hospitalized patients with COVID-19  
26 infection. We included 5,621 patients who had been discharged from isolation or had died  
27 from COVID-19 by April 30, 2020. The primary outcome was composites of death,  
28 admission to intensive care unit (ICU), use of mechanical ventilator or extracorporeal  
29 membrane oxygenation. The secondary outcome was mortality. Multivariate Cox  
30 proportional hazard model was used to evaluate CCIS as the independent risk factor for death.  
31 Among 5,621 patients, the high CCIS ( $\geq 3$ ) group showed higher proportion of elderly  
32 population and lower plasma hemoglobin and lower lymphocyte and platelet counts. The  
33 high CCIS group was an independent risk factor for composite outcome (HR 3.63, 95% CI  
34 2.45-5.37,  $P < 0.001$ ) and patient mortality (HR 22.96, 95% CI 7.20-73.24,  $P < 0.001$ ). The  
35 nomogram demonstrated that the CCIS was the most potent predictive factor for patient  
36 mortality. The predictive nomogram using CCIS for the hospitalized patients with COVID-19  
37 may help clinicians to triage the high-risk population and to concentrate limited resources to  
38 manage them.

## 39 INTRODUCTION

40 The coronavirus disease 2019 (COVID-19) has been declared as a pandemic by the  
41 World Health Organization in March 2020<sup>1</sup>, and as of July 31, 2020, 16,864,828 people have  
42 been affected by the virus and 663,580 deaths were reported worldwide<sup>2</sup>. The Korean Centers  
43 for Disease Control and Prevention (KCDC) and relevant organization prepared policies for  
44 management for the COVID-19 outbreak as soon as the first case of COVID-19 was reported  
45 in Korea<sup>3</sup>. The Korean government not only performed extensive confirmatory tests for those  
46 who are suspected to have the disease but also implemented strict social distancing to prevent  
47 further transmission of disease. As the results, mild cases among young and healthy  
48 population were diagnosed as COVID-19 by screening tests but subsequent case fatality rate  
49 revealed lower than those reported worldwide. As of July 31, there were 14,269 confirmed  
50 cases of COVID-19 and 300 deaths in Korea (case fatality rate of 2.1% in Korea vs. 3.9% in  
51 average worldwide)<sup>4</sup>.

52 Nevertheless, there were some population with higher morbidity and mortality during  
53 COVID-19 outbreak. The situation reports from KCDC demonstrated that higher mortality  
54 among the patients with advanced age<sup>4</sup>. It is reasonable to think that the patients with  
55 advanced age show higher mortality because of reduced immunity and higher comorbidities  
56 such as diabetes or chronic kidney disease. Previous reports suggested old age and multiple  
57 comorbidities are independently associated with higher mortality<sup>5-7</sup>. However, most of the  
58 studies demonstrated individual category of disease such as diabetes or coronary heart disease  
59 as a risk factor but not weighted the effect of age and severity of multimorbidity as predictors  
60 of poor clinical outcomes.

61 Age-adjusted Charlson comorbidity index score (CCIS) has been developed and

62 validated to predict the risk of mortality for use in longitudinal studies<sup>8</sup>. The score can be  
63 calculated from a weighted index consisted of age and the number and seriousness of  
64 comorbid diseases. The CCIS has been widely used to predict 10-year mortality among  
65 hospitalized patients<sup>8</sup>. The CCIS also has been validated in a various disease conditions such  
66 as acute stroke<sup>9,10</sup>, leukemia<sup>11</sup>, end stage renal disease<sup>12,13</sup>, and hip fracture<sup>14,15</sup>.

67 Recently, KCDC released COVID-19 database to the public. The database contains the  
68 clinical and epidemiologic data of 5,628 confirmed cases as well as their clinical outcome  
69 until April 30, 2020. We evaluated patient mortality and clinical outcome according to CCIS  
70 among the hospitalized patients with COVID-19 in Korea.

71

## 72 **RESULTS**

### 73 **Baseline characteristics of the Korean COVID-19 cohort**

74 The baseline characteristics of 5,621 patients are shown in Table 1. The mean duration from  
75 diagnosis to death or release from isolation was 25.6 days. The patients in 50s was the largest  
76 age group followed by those in 20s (Figure 1). The 3,304 (58.8%) patients were female.  
77 Female was predominant throughout all age groups except those younger than 20.  
78 Hypertension (21.3%) and diabetes mellitus (12.3%) were the most common two  
79 comorbidities. It was followed by dementia (4.2%), chronic heart disease (3.2%), malignancy  
80 (2.5%), asthma (2.3%), chronic liver disease (1.5%), congestive heart failure (1.0%), chronic  
81 kidney disease (1.0%), chronic obstructive pulmonary disease (0.7%), and connective tissue  
82 disease (0.7%) (Figure 1). The patients with low systolic blood pressure (BP) (<120mmHg)  
83 and diastolic BP (<80mmHg) were 1317 (24.0%) and 2113 (38.5%), respectively. Among  
84 5621 confirmed cases, asymptomatic infection comprised of 25.8%. Among symptomatic

85 patients, three most common symptoms were cough (41.7%), sputum (28.8%), and febrile  
86 sense (23.2%).

87 The median score of CCIS was 2 (IQR, 0-3). The number of patients in CCIS score 0, 1-2, 3-  
88 4,  $\geq 5$  group was 1,890 (33.6%), 1,791 (31.9%), 1,399 (24.9%), and 541 (9.6%), respectively.

89 Compared to the low CCIS group ( $<3$ ), the high CCIS group ( $\geq 3$ ) showed higher proportion  
90 of elderly patients and medical comorbidities. Presence of dyspnea, altered mentality, and  
91 nausea/vomiting at admission were more frequent in the high CCIS group. In addition, the  
92 number of lymphocyte and platelet count and plasma hemoglobin (Hb) level were  
93 significantly lower in high CCIS group compared to low CCIS group.

94

#### 95 **Clinical outcomes according to CCIS**

96 Composite events occurred in 368 patients (6.6 %) during the follow up period including 234  
97 (4.2 %) deaths, 187 (3.3 %) admission cases of intensive care unit (ICU), 52 (0.9 %) cases of  
98 mechanical ventilation, and 11 (0.2%) cases of extracorporeal membrane oxygenation  
99 (ECMO) application. The composite outcomes occurred more frequently in high CCIS  
100 groups showing 178 patients (32.9 %) in CCIS  $\geq 5$  followed by 135 (9.7%) in CCIS 3-4, 36  
101 (2.0%) in CCIS 1-2, and 19 (1.0%) in CCIS 0 (Table 2). The mortality rate was also higher in  
102 high CCIS groups demonstrating 154 patients (28.5%) in CCIS  $\geq 5$  followed by 68 (4.9%) in  
103 CCIS 3-4, 11 (0.6%) in CCIS 1-2, and 1 (0.1%) in CCIS 0 (Figure 2).

104

#### 105 **Risk factors for severe clinical outcomes**

106 We performed multivariate Cox proportional analysis to find out high CCIS  $\geq 3$  was an

107 independent risk factor for composite outcome (hazard ratio (HR), 3.63 [95% confidence  
108 interval (CI), 2.45-5.37],  $P < 0.001$ ) together with male sex (HR, 1.76 [95% CI 1.32–2.34],  $P$   
109  $< 0.001$ ), body mass index (BMI)  $< 18.5 \text{ kg/m}^2$  (HR, 2.36 [95% CI 1.49–3.75],  $P < 0.001$ ),  
110 presence of dyspnea (HR, 2.88 [95% CI 2.16–3.83],  $P < 0.001$ ), lymphopenia (HR, 2.15 [95%  
111 CI 1.59-2.91],  $P < 0.001$ ), and anemia (HR, 1.80 [95% CI 1.33-2.43],  $P < 0.001$ ) (See Figure  
112 3 and Supplementary Table S1 online).

113 Then, we analyzed the risk factors for mortality (see Supplementary Figure S1 online). The  
114 patients older than 70 years old demonstrated higher mortality risk compared younger  
115 patients. The patients with high CCIS  $\geq 3$  also showed higher risk for mortality compared to  
116 low CCIS group. When we assessed the risk factors for mortality in univariate analysis, old  
117 age  $\geq 70$  years, male sex, high CCIS  $\geq 3$ , anemia, lymphopenia, and thrombocytopenia were  
118 significantly associated with higher mortality rate. In multivariate Cox proportional analysis,  
119 risk of mortality was higher in patients with CCIS  $\geq 3$  (HR, 22.96 [95% CI 7.20 - 73.24],  $P <$   
120  $0.001$ ), male sex (HR, 1.55 [95% CI 1.05–2.29],  $P = 0.027$ ), BMI  $< 18.5 \text{ kg/m}^2$  (HR, 2.88 [95%  
121 CI 1.66–4.99],  $P < 0.001$ ), presence of dyspnea (HR, 2.90 [95% CI 1.96–4.29],  $P < 0.001$ ),  
122 lymphopenia (HR, 2.61 [95% CI 1.75-3.89],  $P < 0.001$ ), anemia (HR, 2.08 [95% CI 1.40-  
123 3.11],  $P < 0.003$ ), and thrombocytopenia (HR, 2.03 [95% CI 1.35–3.04],  $P < 0.001$ ) (Figure 3).

124

### 125 **Prediction model for case fatality**

126 The predictive nomogram was constructed based on the multivariate Cox analysis for  
127 mortality. To calculate 14-, and 28-day overall survival probability was calculated from the  
128 summed points of sex, BMI, CCIS, presence of dyspnea, plasma Hb, lymphopenia, and  
129 thrombocytopenia (Figure 4). The nomogram showed that CCIS was the most important

130 factor contributing to the prognosis followed by the presence of dyspnea, low BMI <18.5  
131 kg/m<sup>2</sup>, lymphopenia (<0.8 x10<sup>9</sup>/L), thrombocytopenia (<150.0 x10<sup>9</sup>/L), anemia (<12.0 g/dL),  
132 and male sex. The Harrell concordance index (C-index) value for prediction of overall  
133 survival was 0.933, and R<sup>2</sup> value was 0.991 in 14-day and 0.990 in 28-day prediction model  
134 (see Supplementary Figure S2 online).

135

## 136 **DISCUSSION**

137 In this study, we described the effect of age and comorbidity upon composites of severe  
138 clinical outcomes (death, ICU admission, mechanical ventilation, or ECMO) among the  
139 hospitalized patients with COVID-19. The patients with high CCIS showed older age, lower  
140 plasma level of Hb, and lower lymphocyte and platelet counts. The high CCIS (≥3) group  
141 was an independent risk factors for composite outcome (HR 3.63, 95% CI 2.45-5.37,  
142 p<0.0001) and patient mortality (HR 7.05, 95% CI 2.13-23.33, p=0.0014).

143 Korean COVID-19 cohort demonstrated large proportion of younger population with age <50  
144 (34.7%) and asymptomatic confirmed cases (25.7%). The patients without any comorbidities  
145 (CCIS 0) comprised of 33.1% of total population. Median CCIS was 2 for the Korean  
146 COVID-19 cohort. Previous report from Wuhan, China demonstrated higher proportion of  
147 younger population with age <50 (56.0%) as well as greater proportion of the patients  
148 without any comorbidities (76.3%)<sup>16</sup>. The brief report from Danish population also  
149 demonstrated that higher proportion of confirmed cases without any comorbidities (CCIS 0,  
150 65.0%)<sup>17</sup>. On the other hands, previous papers from United States of America demonstrated  
151 higher proportion of older people (mean age of 61.0) and lower proportion of the patients  
152 without existing comorbidities (27.4%)<sup>18</sup>. In Italy where one of the highest case fatality rates

153 were reported, the non-survivor demonstrated advanced age ( $79.6\pm 0.9$  years vs.  $64.7\pm 0.4$   
154 years,  $p=0.0001$ ) and higher CCIS ( $4.3\pm 0.15$  vs.  $2.6\pm 0.05$ ,  $p=0.0001$ ) compared to survivors<sup>5</sup>.

155 The observed differences of baseline characteristics among various countries may be related  
156 not only to patient demographics but also the degree of performing active screening tests  
157 against asymptomatic population.

158 Our study is the first large nationwide cohort study to demonstrate that CCIS is the best  
159 predictor for severe clinical outcome in the patients with COVID-19. Previous paper by Chen  
160 et al. demonstrated that advanced age is the strongest risk factor for a fatal outcome<sup>6</sup>. In  
161 addition to advanced age, preexisting comorbid conditions including coronary heart disease  
162 and cerebrovascular disease, shortness of breath, and levels of procalcitonin and aspartate  
163 aminotransferase were related to fatal outcome. However, previous study by Zhou et al.  
164 presented only advanced age but not comorbidity was an independent risk factor for  
165 mortality<sup>19</sup>. Another study by Ji et al. also evaluated the risk factors for progression risk of  
166 pneumonia in COVID-19 patients<sup>20</sup>. They showed that presence of comorbidities and  
167 advanced age both contribute to higher risk of disease progression. Korean group also  
168 recently published the paper about the impact of comorbidities upon the mortality<sup>7,21</sup>.  
169 However, these studies did not use CCIS to calculate the weight of the comorbidities. There  
170 were several studies suggesting CCIS as an independent risk factor for hospitalization or  
171 patient mortality among the patients with COVID-19<sup>17,18,22</sup>. However, to our knowledge,  
172 there was no study showing prediction model of fatal outcome using CCIS.

173 In the same vein with previous studies, the advanced age  $>50$  years old demonstrated high  
174 risk of mortality and ICU admission. The previous study performed by Sung et al. showed  
175 relatively young patients under age 50 recovered without oxygen therapy or ICU care<sup>23</sup>. On  
176 the other hands, the patients of  $\geq 50$  years of age demonstrated high case fatality rate reaching

177 14% in the patients over 80 years old. Our study also confirmed that advanced age itself is an  
178 independent factor for composites of severe clinical outcome.

179 There are some limitations to our study. First, the nationwide database from KCDC only  
180 offered limited data. For example, there are no information about chest radiograph findings or  
181 laboratory findings such as C-reactive protein or serum creatinine. Therefore, we could not  
182 adjust potential risk factors in our study. Second, due to the nature of survey without  
183 collecting actual previous medical history from ICD-10 diagnosis code, some information  
184 about comorbidities are missing. Therefore, we modified some categories of chronic illness  
185 included in the original CCIS. For example, we scored all forms of coronary artery disease  
186 including myocardial infarction and chronic heart disease with a score of 1. Previous report  
187 also demonstrated the usefulness of modified form of CCIS in prediction of clinical outcome  
188 in renal patients<sup>24</sup>. In addition, the information about some chronic conditions such as  
189 peripheral vascular disease, cerebrovascular disease or peptic ulcer disease were missing. We  
190 calculated CCIS based on the available data excluding those categories of missing data.  
191 Therefore, CCIS in our cohort may be underestimated than actual CCIS. Lastly, there can be  
192 ethnic or racial difference in clinical outcomes of COVID-19. Therefore, our result may not  
193 be applied to the different ethnicity or population. However, recent paper suggested that  
194 racial difference did not contribute to different clinical outcome<sup>22</sup>. Nevertheless, there should  
195 be a validation test in each population using our predictive tool before clinical application.

196 In conclusion, our study provided convenient predictive tool using CCIS for the hospitalized  
197 patients with COVID-19 to calculate the risk of severe clinical outcome at admission. The  
198 CCIS together with initial symptom and laboratory findings may lead us to triage the patients  
199 most likely to progress and concentrate our efforts to save their lives.

200

## 201 **METHODS**

### 202 **Study design and participants**

203 This is a retrospective cohort study using the nationwide COVID-19 database provided by  
204 KCDC. A total of 5,628 patients were included in the database who had been confirmed to  
205 have COVID-19 and had received treatment from 100 hospitals until April 30, 2020. Among  
206 them, 7 patients who were confirmed for COVID-19 after death were excluded, and a total of  
207 5,621 patients were included in the analysis. According to the definition provided by the  
208 KCDC<sup>25</sup>, the confirmed case was defined as a patient who had been confirmed to be infected  
209 with COVID-19 by real-time reverse transcriptase-polymerase chain reaction assay or virus  
210 isolation from nasal and/or pharyngeal swab specimens regardless of the clinical symptoms.  
211 The study protocol was reviewed and approved by the Institutional Review Board of the  
212 Kangnam Sacred Heart Hospital, Seoul, Korea (HKS 2020-06-025). The informed consent  
213 was waived due to retrospective nature of the study.

214

### 215 **Data collection**

216 Clinical and epidemiological data were collected in a retrospective manner and were  
217 anonymized before release. Demographic data including age by decade, sex, survival status,  
218 and duration of isolation were collected. Information about whether the patient was admitted  
219 to ICU or applied mechanical ventilator or ECMO were also collected. The BMI, systolic and  
220 diastolic BP, heart rate, and body temperature at initial visit were also measured and reported.  
221 The clinical symptoms associated with COVID-19 were reported including febrile sense,

222 cough, sputum, sore throat, rhinorrhea, myalgia, shortness of breath, headache, altered  
223 consciousness/confusion, nausea or vomiting, diarrhea. Laboratory assessments consisted of  
224 plasma Hb, white blood cell, lymphocyte, and platelet count. The categories of comorbidities  
225 were assessed including diabetes mellitus, hypertension, heart failure, chronic heart disease,  
226 asthma, chronic obstructive pulmonary disease, chronic kidney disease, malignancy, chronic  
227 liver disease, connective tissue disease, and dementia. The CCIS was calculated using the  
228 method described in the previous study<sup>8,24</sup>. Due to lack of available data, all kinds of chronic  
229 heart disease were considered to have congestive heart failure and all forms of chronic liver  
230 disease were considered to have mild liver disease. The presence of peripheral vascular  
231 disease, cerebrovascular disease, peptic ulcer disease, hemiplegia, end-stage renal disease, or  
232 acquired immunodeficiency syndrome could not be known from the current database. All  
233 kinds of malignancy were considered non-metastatic.

234

### 235 **Study outcomes**

236 The primary endpoint was defined as the composite of death, admission to ICU, application  
237 of mechanical ventilation or ECMO. The secondary endpoints were patient mortality and  
238 ICU admission rate. The primary and secondary endpoints were compared between low and  
239 high CCIS groups. Finally, we established a prediction model for patient mortality through  
240 risk factor analysis.

241

### 242 **Statistical Analysis**

243 The baseline characteristics and clinical outcomes were compared among CCIS groups. We

244 divided the patients into 4 groups according to CCIS: CCIS 0, 1-2, 3-4, and  $\geq 5$ . The normally  
245 distributed numerical variables were expressed as the mean  $\pm$  standard deviation, whereas  
246 variables with skewed distributions were expressed as the median and interquartile range.  
247 Statistical comparisons between continuous variables were performed with an independent  
248 Student t-test or one-way analysis of variance for more than two group. For the data without  
249 normal distribution, the Wilcoxon Signed Rank Test for two groups or Kruskal Wallis Test for  
250 more than two groups were performed. The  $\chi^2$  test and Fisher exact test were applied to  
251 categorical variables as appropriate.

252 The Kaplan-Meier method was used to compare composite events-free survival curves, and  
253 differences were assessed utilizing the log-rank test. We used univariate and multivariate Cox  
254 proportional hazard model to estimate risk factors associated with composite outcome and  
255 patient mortality. Age was excluded from the multivariate analysis because of its potential  
256 interaction with CCIS. We used univariate and multivariate logistic regression models to  
257 evaluate the risk factors for ICU admission or use of mechanical ventilation. We used  
258 categorical variables to assess independent risk factors for clinical outcomes as follows: age  
259 group of  $<50$  (reference), 50-69, and  $\geq 70$  years, female (reference) vs. male, BMI  $\geq 18.5$   
260 (reference) vs.  $<18.5$  kg/m<sup>2</sup>, systolic BP  $\geq 120$  (reference) vs.  $<120$  mmHg, diastolic BP  $\geq 80$   
261 (reference) vs.  $<80$  mmHg, heart rate  $<100$  (reference) vs.  $\geq 100$  beats per minute, body  
262 temperature  $<37.5$  (reference) vs.  $\geq 37.5$ °C, CCIS  $<3$  (Reference) vs.  $\geq 3$  points, lymphocyte  
263 count  $\geq 0.8$  (reference) vs.  $<0.8 \times 10^9/L$ , Hb  $\geq 12.0$  (reference) vs.  $<12.0$  g/dL, and platelet  
264 count  $\geq 150.0$  (reference) vs.  $<150.0 \times 10^9/L$ .

265 A nomogram to predict 14-day and 28-day mortality risk of the patient was built based on the  
266 variables found in multivariate Cox proportional hazard model. In the nomogram, CCIS was  
267 used as a variable as a continuous variable to check the impact per CCIS. The maximum

268 score of each variable was set as 100. The performance of the nomogram was measured  
269 based on the C-index. The nomogram was validated in calibration plots with 1,000 bootstrap  
270 samples in which the estimated survival probability was compared with the observed value.  
271 All statistical analysis was performed by using R version 4.0.2 (R Foundation for Statistical  
272 Computing; <http://www.r-project.org/>). P value < 0.05 was considered statistically significant.

273

#### 274 **Data Availability Statement**

275 The data that support the findings of this study are available from KCDC, but restrictions  
276 apply to the availability of these data and so are not publicly available. Data are however  
277 available from the authors upon request and with permission of KCDC.

278 **REFERENCES**

- 279 1 WHO. *Novel Coronavirus (2019-nCoV) Situation Report-51*,  
280 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10)  
281 [sitrep-51-covid-19.pdf?sfvrsn=1ba62e57\\_10](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10).> (2020).
- 282 2 WHO. *Novel Coronavirus (2019-nCoV) Situation Report-186*,  
283 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200724-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200724-covid-19-sitrep-186.pdf?sfvrsn=4da7b586_2)  
284 [covid-19-sitrep-186.pdf?sfvrsn=4da7b586\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200724-covid-19-sitrep-186.pdf?sfvrsn=4da7b586_2).> (2020).
- 285 3 Park, H. C. *et al.* Korean clinical practice guidelines for preventing transmission of  
286 coronavirus disease 2019 (COVID-19) in hemodialysis facilities. *Kidney Res Clin*  
287 *Pract* **39**, 145-150, doi:10.23876/j.krcp.20.046 (2020).
- 288 4 KCDC. *Updates on COVID-19 in Republic of Korea(as of 29 July)*,  
289 [http://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&brdGubun=125&dataGubun](http://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&brdGubun=125&dataGubun=&ncvContSeq=&contSeq=&board_id=>)  
290 [=&ncvContSeq=&contSeq=&board\\_id=>](http://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&brdGubun=125&dataGubun=&ncvContSeq=&contSeq=&board_id=>) (2020).
- 291 5 Iaccarino, G. *et al.* Age and Multimorbidity Predict Death Among COVID-19 Patients:  
292 Results of the SARS-RAS Study of the Italian Society of Hypertension. *Hypertension*  
293 **76**, 366-372, doi:10.1161/HYPERTENSIONAHA.120.15324 (2020).
- 294 6 Chen, R. *et al.* Risk Factors of Fatal Outcome in Hospitalized Subjects With  
295 Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest* **158**, 97-105,  
296 doi:10.1016/j.chest.2020.04.010 (2020).
- 297 7 Kim, D. W., Byeon, K. H., Kim, J., Cho, K. D. & Lee, N. The Correlation of  
298 Comorbidities on the Mortality in Patients with COVID-19: an Observational Study  
299 Based on the Korean National Health Insurance Big Data. *J Korean Med Sci* **35**, e243,  
300 doi:10.3346/jkms.2020.35.e243 (2020).
- 301 8 Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of

- 302 classifying prognostic comorbidity in longitudinal studies: development and  
303 validation. *J Chronic Dis* **40**, 373-383, doi:10.1016/0021-9681(87)90171-8 (1987).
- 304 9 Liu, H. *et al.* Effect of Comorbidity Assessed by the Charlson Comorbidity Index on  
305 the Length of Stay and Mortality Among Immobile Hemorrhagic Stroke Patients  
306 Younger Than 50 Years. *Front Neurol* **11**, 487, doi:10.3389/fneur.2020.00487 (2020).
- 307 10 Ofori-Asenso, R. *et al.* Effect of Comorbidity Assessed by the Charlson Comorbidity  
308 Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for  
309 Acute Stroke. *Int J Environ Res Public Health* **15**, doi:10.3390/ijerph15112532 (2018).
- 310 11 Dhakal, P. *et al.* Usefulness of Charlson Comorbidity Index to Predict Early Mortality  
311 and Overall Survival in Older Patients With Acute Myeloid Leukemia. *Clin*  
312 *Lymphoma Myeloma Leuk*, doi:10.1016/j.clml.2020.07.002 (2020).
- 313 12 Park, J. Y. *et al.* Comorbidities Can Predict Mortality of Kidney Transplant Recipients:  
314 Comparison With the Charlson Comorbidity Index. *Transplant Proc* **50**, 1068-1073,  
315 doi:10.1016/j.transproceed.2018.01.044 (2018).
- 316 13 Chae, J. W. *et al.* Prediction of mortality in patients undergoing maintenance  
317 hemodialysis by Charlson Comorbidity Index using ICD-10 database. *Nephron Clin*  
318 *Pract* **117**, c379-384, doi:10.1159/000321525 (2011).
- 319 14 Toson, B., Harvey, L. A. & Close, J. C. The ICD-10 Charlson Comorbidity Index  
320 predicted mortality but not resource utilization following hip fracture. *J Clin*  
321 *Epidemiol* **68**, 44-51, doi:10.1016/j.jclinepi.2014.09.017 (2015).
- 322 15 Kirkland, L. L., Kashiwagi, D. T., Burton, M. C., Cha, S. & Varkey, P. The Charlson  
323 Comorbidity Index Score as a predictor of 30-day mortality after hip fracture surgery.  
324 *Am J Med Qual* **26**, 461-467, doi:10.1177/1062860611402188 (2011).
- 325 16 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N*

- 326 *Engl J Med* **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
- 327 17 Christensen, D. M. *et al.* Charlson Comorbidity Index Score and Risk of Severe  
328 Outcome and Death in Danish COVID-19 Patients. *J Gen Intern Med*,  
329 doi:10.1007/s11606-020-05991-z (2020).
- 330 18 Imam, Z. *et al.* Older age and comorbidity are independent mortality predictors in a  
331 large cohort of 1305 COVID-19 patients in Michigan, United States. *J Intern Med*,  
332 doi:10.1111/joim.13119 (2020).
- 333 19 Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with  
334 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062,  
335 doi:10.1016/S0140-6736(20)30566-3 (2020).
- 336 20 Ji, D. *et al.* Prediction for Progression Risk in Patients with COVID-19 Pneumonia:  
337 the CALL Score. *Clin Infect Dis*, doi:10.1093/cid/ciaa414 (2020).
- 338 21 Cho, J. H. *et al.* Hemodialysis with Cohort Isolation to Prevent Secondary  
339 Transmission during a COVID-19 Outbreak in Korea. *J Am Soc Nephrol* **31**, 1398-  
340 1408, doi:10.1681/ASN.2020040461 (2020).
- 341 22 Price-Haywood, E. G., Burton, J., Fort, D. & Seoane, L. Hospitalization and Mortality  
342 among Black Patients and White Patients with Covid-19. *N Engl J Med* **382**, 2534-  
343 2543, doi:10.1056/NEJMsa2011686 (2020).
- 344 23 Sung, H. K. *et al.* Clinical Course and Outcomes of 3,060 Patients with Coronavirus  
345 Disease 2019 in Korea, January-May 2020. *J Korean Med Sci* **35**, e280,  
346 doi:10.3346/jkms.2020.35.e280 (2020).
- 347 24 Beddhu, S., Bruns, F. J., Saul, M., Seddon, P. & Zeidel, M. L. A simple comorbidity  
348 scale predicts clinical outcomes and costs in dialysis patients. *Am J Med* **108**, 609-613,  
349 doi:10.1016/s0002-9343(00)00371-5 (2000).

350 25 KCDC. *Patient treatment and management: case definitions,*  
351 [http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=112&dataGubun=&ncvContSeq=&contSeq=&board\\_id=](http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=112&dataGubun=&ncvContSeq=&contSeq=&board_id=)  
352 [http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=112&dataGubun=&ncvContSeq=&contSeq=&board\\_id=](http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=112&dataGubun=&ncvContSeq=&contSeq=&board_id=) (2020).

353 **Acknowledgements**

354 We acknowledge all the health-care workers involved in the diagnosis and treatment of  
355 COVID-19 patients in South Korea. We thank the Central Disease Control Headquarters,  
356 National Medical Center and the Health Information Manager in 100 hospitals for their effort  
357 in collecting the medical records. There was no specific funding for this work.

358

359 **Authors' contributions**

360 All authors participated in the research and preparation of the manuscript. K.D.H. and P.H.C.  
361 equally contributed to this manuscript as 1<sup>st</sup> authors who drafted this paper. P.H.C. and L.Y.K.  
362 contributed to the conception of the work and study design. K.J.S. contributed to statistical  
363 analyses and producing tables and figures. K.D.H., K.J., and Y.K.S. contributed to the  
364 acquisition of data and manipulating the data to the analyzable format. L.Y.K. had full access  
365 to all the data in the study and take responsibility for the integrity and accuracy of the data.  
366 C.A. and L.Y.K. supervised the work and revised the manuscript.

367

368 **Competing interests**

369 The authors declare that they have no competing interests.

370 **FIGURE LEGENDS**

371 **Figure 1. Demographic distribution of the patients with COVID-19 in Korea. A. Age**  
372 **and sex distribution; B. Proportion of underlying comorbidities.**

373 The patients in 50s was the largest age group followed by those in 20s. Female was  
374 predominant throughout all age groups except those younger than 20. Hypertension (21.3%)  
375 and diabetes mellitus (12.3%) were the most common two comorbidities. It was followed by  
376 dementia (4.2%), chronic heart disease (3.2%), malignancy (2.5%), asthma (2.3%), chronic  
377 liver disease (1.5%), congestive heart failure (1.0%), chronic kidney disease (1.0%), chronic  
378 obstructive pulmonary disease (0.7%), and connective tissue disease (0.7%)

379 *Abbreviations.* CHF, Congestive heart failure; CKD, Chronic kidney disease; CLD, Chronic  
380 liver disease; COPD, Chronic obstructive pulmonary disease; COVID-19, coronavirus  
381 disease 2019; CTD, Connective tissue disease; HTN, hypertension.

382

383 **Figure 2. Proportion of death according to CCIS of patients with COVID-19.**

384 The morality rate increased as CCIS increases. The mortality rate was 28.5% in CCIS  $\geq 5$   
385 followed by 4.9% in CCIS 3-4, 0.6% in CCIS 1-2, and 0.1% in CCIS 0.

386 *Abbreviations.* CCIS, age-adjusted Charlson comorbidity index score; COVID-19,  
387 coronavirus disease 2019.

388

389 **Figure 3. Risk factor for severe clinical outcomes in the patients with COVID-19. A.**  
390 **Risk factors for the composite outcome; B. Risk factors for patient mortality.**

391 Multivariate Cox proportional hazard model demonstrated CCIS is an independent risk factor  
392 for composite outcome and mortality after adjusting other risk factors.



393 *Abbreviations.* BMI, body mass index; BP blood pressure; CCIS, age-adjusted Charlson  
394 comorbidity index score; CI, confidence interval; COVID-19, coronavirus disease 2019.


395


396 **Figure 4. Prognostic nomogram for prediction of the overall survival probability of**  
397 **patients with COVID-19.**

398 The nomogram demonstrates CCIS is the potent predictor for 14-day and 24-day survival of  
399 the patients.

400 *Abbreviations.* BMI, body mass index; CCIS, age-adjusted Charlson comorbidity index score;  
401 COVID-19, coronavirus disease 2019.

**A****B**



**A****B**